Louis Jansen carries out research into the treatment of chronic hepatitis B (CHB). Currently, two types of drugs are approved for the treatment of CHB patients: conventional or pegylated interferon alpha (IFNα or Peg- IFNα) and nucleoside or nucleotide analogues (NAs). Jansen’s main focus is to establish predictors of response to Peg- IFNα-based therapy, which may ultimately allow the selection of those patients most likely to benefit from treatment and prevent unnecessary treatment in others.
L. Jansen: Virus-Host Interplay in Chronic Hepatitis B. Predicting Response to Immunomodulating Antiviral Therapy.
Prof. H.L. Zaaijer
Prof. U.H.W. Beuers
Dr H.W. Reesink
Dr N.A. Kootstra
This event is open to the public.